Sains Malaysiana 50(8)(2021): 2367-2377 http://doi.org/10.17576/jsm-2021-5008-19

Gestational Diabetes in Malaysia: A Systematic Review of Prevalence, Risk Factors and Outcomes

(Diabetes Gestasi di Malaysia: Suatu Kajian Sistematik Mengenai Prevalens, Faktor Risiko dan Akibat)

CHEONG LIENG TENG*, FOO KEN YONG, KA MUN LUM, SHEN YUNG TOH, CHAN XUAN HII & SIVALINGAM NALLIAH

ABSTRACT

Gestational diabetes mellitus (GDM) is glucose intolerance first diagnosed during pregnancy. In Malaysia, the prevalence, risk factors, and maternal/foetal outcomes vary somewhat among the local studies. In this systematic review of Malaysian studies, we synthesise relevant data from 13 journal articles (including 10,285 women with gestational diabetes). A meta-analysis of twelve datasets showed a prevalence of 21.5% (95% CI 17.3 to 25.9%, random effect model). Clinical factors in the mother found to increase her risk of GDM were consistent with international data. A meta-analysis of complications showed statistically significant increase for macrosomia (OR 3.08, 95% CI 1.77 to 5.36) but not for pre-eclampsia (OR 1.44, 95% CI 0.52 to 4.00) and caesarean delivery (OR 1.31, 95% CI 0.98 to 1.75). The high prevalence of gestational diabetes mellitus and documented adverse consequences support the need for universal screening of this condition in all pregnant women in Malaysia.

Keywords: Gestational diabetes; Malaysia; pregnancy; prevalence; risk factors

ABSTRAK

Diabetes gestasi (GDM) adalah keadaan intolerans glukosa yang pertama kali dikesan semasa kehamilan. Di Malaysia, prevalens, faktor risiko dan akibat penyakit ini agak berbeza di kalangan penyelidikan tempatan. Dalam kajian sistematik ke atas penyelidikan dari Malaysia, kami menggabungkan data daripada 13 artikel jurnal (termasuk 10,285 wanita yang mengidap diabetes gestasi). Analisa meta 12 set data menunjukkan prevalens ialah 21.5% (95% CI 17.3 - 25.9%, model kesan rawak). Faktor klinikal pada ibu yang meningkatkan risiko kepada GDM adalah selaras dengan data antarabangsa. Analisa meta ke atas komplikasi akibat GDM menunjukkan peningkatan signifikan secara statistik bagi makrosomia (OR 3.08, 95% CI 1.77 - 5.36) tetapi tidak untuk praeklampsia (OR 1.44, 95% CI 0.52 - 4.00) dan pembedahan caesarean (OR 1.31, 95% CI 0.98 - 1.75). Prevalens diabetes gestasi yang tinggi dan akibat buruk yang ditunjukkan menyokong perlunya saringan universal bagi penyakit ini di kalangan ibu mengandung di Malaysia. Kata kunci: Diabetes gestasi; faktor risiko; kehamilan; Malaysia; prevalens

INTRODUCTION

Gestational diabetes mellitus (GDM) is glucose intolerance first diagnosed during pregnancy. GDM poses a huge health burden in both the short and long term. Both mother and baby of GDM are at greater risk of complications during pregnancy and delivery. Poorly managed GDM results in higher perinatal morbidity and mortality (Contreras et al. 2008). After delivery, both mother and newborn are also at a greater risk of developing type 2 diabetes mellitus, obesity, and subsequent cardiovascular diseases (Kramer et al. 2019; Nouhjah et al. 2017). Hyperglycaemia in pregnancy is associated with macrosomia and polyhydramnios. During delivery, these infants of poorly controlled GDM will be more susceptible to birth related complications of prolonged labour, shoulder dystocia, birth asphyxia, and increased rates of admission to neonatal intensive care unit (NICU). Caesarean delivery rates are higher in GDM for various reasons apart from estimated birth weight exceeding 4 kg (Boriboonhirunsarn & Waiyanikorn 2016).

The prevalence of GDM varies worldwide depending on the diagnostic criteria and reporting rates. A metaanalysis of 50 population-based prevalence studies showed that Asia has the highest prevalence (South Asia 11.4%, East Asia 10.8%), while lower rates were seen in Australia with 3.6%, North America with 4.5% and North Europe with 6% (Behboudi-Gandevani et al. 2019). Locally, there is some variation in the prevalence, risk factors and maternal/foetal outcomes of this condition. Synthesised data in these domains derived from metaanalysis can help policy makers and clinicians with regard to the implementation of screening programme and clinical care of such patients.

MATERIALS AND METHODS

We searched PubMed (using the MESH terms 'Diabetes', 'Gestational' and 'Malaysia') and Scopus (using text word 'gestational diabetes' and 'Malaysia') on 31st December 2019. These searches were supplemented by a Google Scholar search using the same text words. The citations were processed using Endnote 7 citation manager. Keywords of all citations were coded for study designs, study settings (primary care, tertiary care), country of study (Malaysia, non-Malaysia), and any prevalence, risk factors or maternal or foetal/neonatal outcome data.

The inclusion criteria of eligible studies were: Original research conducted in Malaysia; Studies that provide data on prevalence, risk factors, maternal or foetal/neonatal outcome data of GDM; for prevalence data, GDM must be diagnosed using an oral glucose tolerance test (oGTT); for risk factor assessment, the recruitment of antenatal women should be universal rather than selective; and for maternal and foetal/neonatal outcome data, both prospective and retrospective studies are acceptable.

Full text of eligible studies was retrieved. Relevant data in the included studies were extracted by a pair of investigators and checked by a senior researcher. The number of study participants (total sample and number diagnosed with GDM) and other relevant data (study setting, patient selection, oGTT method) were extracted. Meta-analysis was performed using MedCalc Statistical Software using fixed effect model if study heterogeneity (I²) is less than 50%, otherwise random effect model was used (MedCalc 2019). Sensitivity analysis was performed for prevalence data taking into account the study setting, patient selection and oGTT procedure.

This systematic review was prepared following PRISMA guideline (Moher et al. 2009). The quality assessment of the published studies was assessed using a checklist published by Munn et al. (2015).




FIGURE 1. PRISMA 2009 flow diagram

RESULTS

SEARCH RESULTS

Of the 124 items found from the database and internet search, we included 15 publications in the qualitative analysis (Basri et al. 2018; Gill et al. 2012; Goh et al. 2018; Hasbullah et al. 2020; Idris et al. 2009; Ismail et al. 2013, 2011; Kalok et al. 2018; Kampan et al. 2013; Logakodie et al. 2018; Muniswaran et al. 2017; Nordin et al. 2006; Shamsuddin et al. 2001; Tan et al. 2012, 2007). Two publications with low quality score were excluded (lack of information on the patient recruitment and diagnostic method) (Goh et al. 2018; Muniswaran et al. 2017). Eleven publications provided prevalence data (Basri et al. 2018; Gill et al. 2012; Hasbullah et al. 2020; Idris et al. 2009; Ismail et al. 2013, 2011; Kalok et al. 2018; Logakodie et al. 2018; Shamsuddin et al. 2001; Tan et al. 2012, 2007). Four publications provided risk factors data (Gill et al. 2012; Shamsuddin et al. 2001; Tan et al. 2012, 2007), and seven publications provided maternal, foetal/neonatal complications data (Basri et al. 2018; Ismail et al. 2013, 2011; Kalok et al. 2018; Kampan et al. 2013; Logakodie et al. 2018; Nordin et al. 2006).

QUALITY ASSESSMENT

All the included studies received a moderate to high quality rating in our critical appraisal.

PREVALENCE OF GESTATIONAL DIABETES

Eleven publications provided data on prevalence of GDM (Table 1) (Basri et al. 2018; Gill et al. 2012; Hasbullah et al. 2020; Idris et al. 2009; Ismail et al. 2013, 2011; Kalok et al. 2018; Logakodie et al. 2018; Shamsuddin et al. 2001; Tan et al. 2012, 2007). One publication contained two separate datasets of GDM prevalence (Basri et al. 2018). These studies were conducted in various settings (primary care and tertiary care), and recruited pregnant women with and without risk factors of GDM. Although all of them used oGTT to confirm the presence of GDM, the methods employed in administrating oGTT and diagnostic threshold were highly variable. 1-step procedure (75 g oGTT) was used in seven studies (eight datasets) and 2-step procedure (a 50 g glucose challenge test followed by a 75 g oGTT in selected cases) was done in three studies.

The prevalence rate of GDM in the primary studies ranged from 11.4 to 37.9%, a 3.3-fold difference. A meta-analysis of twelve datasets involving 9587 antenatal women showed very high study heterogeneity (I²=95.97) with a prevalence of 21.5% (95% CI 17.3 to 25.9%, random effect model) (Figure 2). Sensitivity analysis showed no difference in the prevalence by setting. However, prevalence of GDM appeared to be lower if there was less selection bias while 2-step procedure tends to under-detect GDM compared to 1-step procedure (Table 2).

Study	Methods				Participants	Prevalence			
	Study	Recruitment	oGTT	oGTT	Setting	n	Mean	Primigravida,	
	design*		method	criteria			age, y	%	
Basri et al.	RCT	Selective	1-step	FBS>6.1 OR	Tertiary care	261	31.9	32.6	37.9%
(2018)				2HPP>7.8					
				mmol/L					
				[WHO1999]					
Basri et al.	RCT	Selective	1-step	FBS≥5.1 OR	Tertiary care	259	31.1	42.1	38.6%
(2018)				2HPP≥8.5					
				mmol/L					
				[IADPSG]					


TABLE 1. Malaysian studies providing prevalence data of gestational diabetes

Gill et al.	RCS	Universal	2-step	GCT (50 g)	Tertiary care	1997	29.0	NA	21.5%
(2012)				1HPP>7.2;					
				then oGTT					
				(75 g),					
				FBS>6.0,					
				2HPP>7.8					
				mmol/L					
Hasbullah et	PCS	Universal	1-step	FBS>5.1 OR	Primary care	294	30.1	38.1	15.3%
al. (2020)				2HPP>7.8					
				mmol/L					
Idris et al.	CSS	Selective	2-step	GCT (50 g)	Primary care	366	30.3	30.0	18.3%
(2009)				1HPP>7.8;					
				then oGTT					
				(75 g),					
				FBS<7.0					
				AND 2HPP					
Ismail et al.	PCS	Selective**	1-step	≥7.8 mmol/L FBS>6.0 OR	Tertiary care	616	26.6	100	18.3%
(2011)				2HPP>7.8					
				mmol/L					
Ismail et al.	PCS	Selective	1-step	FBS≥6.0 OR	Tertiary care	279	30.9	30.1	22.6%
(2013)				$2\text{HPP} \ge 7.8$					
				mmol/L					
Kalok et al.	PCS	Selective***	1-step	FBS >6.1	Tertiary care	197	31.0	NA	14.2%
(2018)				OR 2HPP					
				>7.8					
Logakodie et	RCS	Selective	1-step	mmol/L FBG ≥5.6 or	Primary care	659	NA	29.3	27.9%
al. (2017)				2HPP ≥7.8	2				
``'				mmol/L					
Shamsuddin	CSS	Universal	1-step	2HPP≥7.8	Tertiary care	768	NA	57.7	24.9%
et al. (2001)				mmol/L (no					
				FBS)					

Tan et al.	PCS	Universal	2-step	GCT (50 g)	Tertiary care	2291	29.8	NA	13.9%
(2012)				1HPP>7.2;					
				then oGTT					
				(75 g),					
				FBS>7.0,					
				2HPP>7.8					
				mmol/L					
Tan et al.	PCS	Universal	2-step	GCT (50 g)	Tertiary care	1600	29.6	42.4	11.4%
(2007)				1HPP>7.2;					
				then oGTT					
				(75 g),					
				FBS>7.0,					
				2HPP>7.8					
				mmol/L					

*CSS=cross-sectional study; PCS=prospective cohort study; RCS=retrospective cohort study; RCT=randomised controlled trial;

only recruited primigravida; *only recruited women with low GDM risk



Test for heterogeneity	
Q	272.6162
DF	11
Significance level	P < 0.0001
I ² (inconsistency)	95.97%
95% CI for I ²	94.36 to 97.11

FIGURE 2. Meta-analysis of prevalence rate of gestational diabetes

Sensitivity analysis	(n=number of datasets)	Prevalence (95%CI), [random effect]	Prevalence (95%CI), [fixed effect]	I^2
Study setting	Primary care (n=3)	20.5 (13.2 to 28.8)	22.2 (20.0 to 24.6)	91.63
	Tertiary care (n=9)	21.8 (16.9 to 27.1)	18.1 (17.2 to 18.9)	96.61
Patient selection*	Universal (n=5)	17.2 (12.5 to 22.3)	16.6 (15.7 to 17.4)	96.42
	Selective (n=5)	28.7 (21.6 to 36.4)	27.9 (25.9 to 30.0)	91.77
OGTT procedure	1-step (n=8)	24.6 (19.3 to 30.2)	24.4 (23.0 to 25.9)	92.52
	2-step (n=4)	16.1 (11.6 to 21.2)	15.8 (14.9 to 16.7)	96.09

TABLE 2. Sensitivity analysis of prevalence meta-analysis (all studies)

*exclude Kalok et al. (2018) and Ismail et al. (2011) (low risk)

RISK FACTORS OF GESTATIONAL DIABETES

We found four studies reporting risk factors for GDM in Malaysia (Gill et al. 2012; Shamsuddin et al. 2001; Tan et al. 2012, 2007). In this analysis, we included only studies that recruited all antenatal women rather those with or without certain risk factors. Clinical factors in the mother found to increase her risk of GDM were: older maternal age, obesity, glycosuria, abnormal GCT, family history of diabetes, previous GDM and history of stillbirth (Table 3).

TABLE 3. Malaysian studies providing risk factors data of gestational diabetes

Study	Methods			Participants		Risk factors
	Study	Recruitment	oGTT method	Setting	n	
	design*					
Gill et al. (2012)	RCS	Universal	2-step	Tertiary care	1997	Older age, booking weight ≥ 80 kg,
						glycosuria, abnormal GCT, family
						history of diabetes, previous GDM,
						history of stillbirth
Shamsuddin et	CSS	Universal	1-step	Tertiary care	768	Previous GDM, maternal age >35
al. (2001)						
Tan et al. (2012)	PCS	Universal	2-step	Tertiary care	2291	Older age, abnormal GCT, maternal
						weight ≥70 kg
Tan et al. (2007)	PCS	Universal	2-step	Tertiary care	1600	Older age, higher maternal BMI,
						higher SBP, higher DBP

*CSS=cross-sectional study; PCS=prospective cohort study; RCS=retrospective cohort study; RCT=randomised controlled trial

MATERNAL AND FOETAL/NEONATAL COMPLICATIONS

We found seven studies that provided maternal, foetal/ neonatal complications data (Basri et al. 2018; Ismail et al. 2013, 2011; Kalok et al. 2018; Kampan et al. 2013; Logakodie et al. 2018; Nordin et al. 2006). One study containing two separate datasets were analysed separately (Basri et al. 2018). Maternal complications that were associated with GDM were caesarean delivery rate, induction of labour, polyhydramnios, pre-eclampsia, and premature labour. Foetal/neonatal, complications that were associated with GDM were birth trauma, hyperbilirubinaemia, hypoglycaemia, low Apgar score, macrosomia, NICU admission, polycythaemia, respiratory distress syndrome, and stillbirth (Table 4). A meta-analysis of complications reported in three or more datasets showed statistically significant increase for macrosomia (OR 3.08, 95% CI 1.77 to 5.36) but not for pre-eclampsia (OR 1.44, 95% CI 0.52 to 4.00) and caesarean section (OR 1.31, 95% CI 0.98 to 1.75) (Table 5).

Study	Methods			Participants		Complications		
	Study	Recruitment	oGTT	Setting	n	Maternal	Foetal/neonatal	
	design*		method					
Basri et al.	RCT	Selective	1-step	Tertiary care	261	Caesarean section	Macrosomia	
(2018)								
Basri et al.	RCT	Selective	1-step	Tertiary care	259	Gestational	Neonatal	
(2018)						hypertension or	hypoglycaemia	
						pre-eclampsia		
Ismail et al.	PCS	Selective**	1-step	Tertiary care	616	None	Hyperbilirubinaemia	
(2011)								
Ismail et al.	PCS	Selective	1-step	Tertiary care	279	Caesarean section,	Macrosomia,	
(2013)						assisted delivery	stillbirth,	
							birth trauma,	
							hypoglycaemia,	
							hyperbilirubinemia,	
	Dee						polycythaemia	
Kalok et al.	PCS	Selective***	1-step	Tertiary care	197	Labour induction,	Macrosomia	
(2018)						caesarean section		
Kampan et al.	CCS	Selective	1-step	Tertiary care	800	Premature labour,	Low Apgar,	
(2013)****						caesarean section	macrosomia,	
							NICU admission,	
							hypoglycaemia,	
							respiratory distress	
Localradia at	RCS	Salaatiya	1 star	Drimory corre	650	Non montonoous	syndrome No data	
Logakodie et	KC3	Selective	1-step	Primary care	659	Non-spontaneous	no dala	
al. (2017)	DCC	0.1 /	1 4	т. ť	200	vaginal delivery	Х.	
Nordin et al.	RCS	Selective	1-step	Tertiary care	298	Polyhydramnios,	Macrosomia	
(2006)						pre-eclampsia,		
						labour induction		

TABLE 4. Malaysian studies providing complications data of gestational diabetes

*CCS=case-control study; PCS=prospective cohort study; RCS=retrospective cohort study; RCT=randomised controlled trial;

recruited primigravida only; *recruited women with low GDM risk only

****Some women in this study had pre-existing diabetes, it is included here as 96% of them had GDM

Outcomes	Number of datasets (references)	f datasets		Odds ratio (95% CI), (random effect)	Odds ratio (95% CI), (fixed effect)	I ²	
		GDM (n/N)	No GDM (n/N)				
Pre-eclampsia	4(9, 13, 16)	28/706	36/1212	1.44 (0.52 to 4.00)	1.51 (0.88 to 2.38)	64.68%	
Caesarean section	4(9, 13, 15)	96/334	227/981	1.35 (0.94 to 1.93)	1.31 (0.98 to 1.75)	30.79%	
Macrosomia	6(9, 13-16)	35/797	28/1597	2.91 (1.54 to 5.47)	3.08 (1.77 to 5.36)	9.09%	

TABLE 5. Meta-analysis of odds ratio of complications of gestational diabetes

n/N=number of participants with complication/number of participants in subgroup

DISCUSSION

PREVALENCE AND RISK FACTORS OF GDM

The pooled prevalence of GDM in Malaysia as shown in our meta-analysis is approximately 21.5% (95% CI 17.3% to 25.9%, random effect model, Table 1). There is some uncertainty in this pooled prevalence in view of high study heterogeneity, possibly as a result of differences in the patient recruitment, diagnostic methods and criteria of oGTT. In the selection of studies for this meta-analysis, we have excluded one retrospective cohort study derived from the Malaysian Obstetric Registry (Muniswaran et al. 2017). Although this study has a large sample size (n=22,044), the antenatal women were recruited at delivery from the obstetrics register of 14 public hospitals. The diagnostic method and criteria of GDM were also not clearly described.

Our pooled prevalence of GDM appeared to be higher than the pooled prevalence for Asian countries (Lee et al. 2018; Nguyen et al. 2018) (10.1-11.5%). In these meta-analyses, only two Malaysian prevalence studies were included (Lee et al. 2018; Nguyen et al. 2018). When compared to the country-specific meta-analyses of prevalence studies, our pooled prevalence is also higher than those of Iran with 3.41% (Jafari-Shobeiri et al. 2015), Turkey with 7.7% (Karaçam & Cellk 2021), China with 14.8% (Gao et al. 2019), and India with 19.19% using IADPSG method of diagnosis (Li et al. 2018).

There are concerns in adopting universal screening for GDM in resource limited countries despite ACHOIS trial had shown intervention for women suffering from mild gestational diabetes did reduce some of its complications such as fetal overgrowth, shoulder dystocia, caesarean delivery, and hypertensive disorders (Landon et al. 2009). However, there appears to be some compelling evidence for the adoption of universal screening for GDM in antenatal mothers in Malaysia. Firstly, the incidence of GDM is substantially high, affecting possibly one in five pregnant women in this country. Secondly, selective screening may miss a substantial number of eligible women, e.g. Shamsuddin et al. (2001) reported 28% of GDM women in their study did not have any risk factors used in the selective screening. Furthermore, Gill et al. (2012) also did not find improved efficiency of GDM screening using a scoring system derived from nine known GDM risk factors.

Currently two Malaysian clinical practice guidelines (HTAU 2017, 2015) recommend screening of antenatal women using 75 g oGTT at booking based on the presence of risk factors, and, if negative, to repeat the same at 24-28 weeks gestation. Both these guidelines adopted the IADPSG guideline (Lapolla et al. 2011) but with some difference for the 2 h post-glucose load threshold (Type 2 Diabetes CPG: FPG \geq 5.1, 2HPP \geq 8.5 (Health Technology Assessment Unit 2015); DM in Pregnancy CPG: FPG \geq 5.1, 2HPP \geq 7.8 (Health Technology Assessment Unit

2017)). The Health Technology Assessment Unit of the Ministry of Health Malaysia, as developer of the national guideline, should initiate efforts to avoid such confusion.

COMPLICATIONS AND OUTCOMES OF GESTATIONAL DIABETES

Our analysis identified several complications as a result of GDM. However, in our meta-analysis, only macrosomia is a statistically significant outcome but not pre-eclampsia or caesarean section. In our literature review, we found that the above complications are by and large associated with GDM in other systematic reviews (Hosseini & Janghorbani 2018; Natamba et al. 2019; Wendland et al. 2012), however, some inconsistency is also found, e.g. Natamba's systematic review (2019) of studies in Sub-Sahara Africa also did not show an increased risk of caesarean section.

STUDY LIMITATIONS

This systematic review is based on a comprehensive retrieval of Malaysian journal articles on the topic of GDM. We are confident that we have identified most, if not all, relevant publications on this topic. However, publication bias cannot be excluded. In addition, pooled analysis is compounded by missing data in the original publications. Furthermore, beside the variable diagnostic methods and threshold for GDM, it is also possible there are inconsistent definitions for other outcomes such as macrosomia and pre-eclampsia. Thus, we wish to echo the call by Feig et al. (2015) for codification of the definitions and reporting of variables in future investigation on GDM.

CONCLUSION

This systematic review comprehensively summarises the available published literature on the prevalence, risk factors, and complications/outcomes of GDM in Malaysian women. Our study emphasised the high prevalence of GDM, summarised various risk factors associated with it and substantial complications that may result and recommend universal screening of this important health condition in pregnancy.

ACKNOWLEDGEMENTS

We wish to thank Dr Fauziah Zainal Ehsan for assisting in the preparation of the Malay abstract.

REFERENCES

- Basri, N.I., Mahdy, Z.A., Ahmad, S., Karim, A.K.A., Shan, L.P., Manaf, M.R.A. & Ismail, N.A.M. 2018. The World Health Organization (WHO) versus The International Association of Diabetes and Pregnancy Study Group (IADPSG) diagnostic criteria of gestational diabetes mellitus (GDM) and their associated maternal and neonatal outcomes. *Hormone Molecular Biology and Clinical Investigation* 34(1): 1-9.
- Behboudi-Gandevani, S., Amiri, M., Yarandi, R.B. & Tehrani, F.R. 2019. The impact of diagnostic criteria for gestational diabetes on its prevalence: A systematic review and metaanalysis. *Diabetology & Metabolic Syndrome* 11(1): 1-18.
- Boriboonhirunsarn, D. & Waiyanikorn, R. 2016. Emergency cesarean section rate between women with gestational diabetes and normal pregnant women. *Taiwan Journal of Obstetrics and Gynecology* 55(1): 64-67.
- Contreras, M., Sacks, D.A., Watson, W., Dooley, S.L., Foderaro, M., Niznik, C., Bjalicik, J., Catalano, P.M., Dierkerm, L., Foz, S., Gullion, L., Johnson, C., Lindsay, C.A., Makovos, H., Sakerm, F., Carpenter, M.W., Hunt, J., Somer, M.H., Amankwah, K.S., Chan, P.C., Gherson, B., Herer, E., Kapur, B., Kenshole, A., Lawrencem, G., Matheson, K., Mayes, L., McLean, K., Owen, H., Cave, C., Fenty, G., Gibson, E., Hennis, A., McIntyre, G., Rotchell, Y.E., Spooner, C., Thomas, H.A.R., Gluck, J., Hadden, D.R., Halliday, H., Irwin, J., Kearney, O., McAnee, J., McMance, D.R., Mousavi, M., Traub, A.I., Cruickshank, J.K., Derbyshire, J., Dry, J., Holt, A.C., Khan, F., Lambert, C., Maresh, M., Princhard, F., Townson, C., Haeften, T.W.V., Hengel, A.M.R.V.D., Visser, G.H.A., Zwart, A., Chaovarindr, U., Chotigeat, U., Deerochanawong, C., Panyasiri, I., Sanguanpong, P., Amichay, D., Golan, A., Marks, K., Mazor, M., Ronen, J., Wiznitzer, A., Chen, R., Harel, D., Hoter, N., Melamed, N., Pardo, J., Withsner, M., Yogev, Y., Bowling, F., Cowley, D., Devenish-Meares, P., Liley, H.G., McArdle, A., McIntyre, H.D., Morrison, B., Peacock, A., Tremellen, A., Tudehope, D., Chan, K.Y., Chan, N.Y., Ip, L.W., Kong, S.L., Lee, Y.L., Li, C.Y., Ng, K.F., Ng, P.C., Rogers, M.S., Wong, K.W., Edgar, M., Giles, W., Gill, A., Glover, R., Lowe, J., Mackenzie, F., Siech, K., Verma, J., Wringht, A., Cao, Y.H., Chee, J.J., Koh, A., Yan, E., Rajadurai, V.J., Wee, H.Y., Yeo, G.S.H., Coustan, D., Haydin, B., Alexander, A., Hadden, D.R., Attias-Raved, O., Hod, M., Oats, J.J.N.M., Parry, A.F., Collard, A., Frank, A.S., Lowe, I.P., Thomas, A., Case, T., Cholod, P., Dyer, A.R., Engelman, L., Xiao, M., Yang, L., Burgess, C.I., Lappin, T.R.J., Nesbull, G.S., Sheridan, B., Smye, M., Trimble, E.R., Coustanm, A., Dyer, A.R., Hadden, D.R., Hod, M., Lowe, L.P., Oats, J.J.N., Persson, B., Trimble, E.R., Cutter, G.R., Gabbe, S.G., Hare, J.W., Wagenknecht, L.E., Chen, Y., Claman, J. & King, J. 2008. Hyperglycemia and adverse pregnancy outcomes. New England Journal of Medicine 358(19): 1991-2002.

- Feig, D.S., Corcoy, R., Jensen, D.M., Kautzky-Willer, A., Nolan, C.J., Oats, J.J., Sacks, D.A., Caimari, F. & McIntyre, H.D. 2015. Diabetes in pregnancy outcomes: A systematic review and proposed codification of definitions. *Diabetes/ Metabolism Research and Reviews* 31(7): 680-690.
- Gao, C., Sun, X., Lu, L., Liu, F. & Yuan, J. 2019. Prevalence of gestational diabetes mellitus in mainland China: A systematic review and meta-analysis. *Journal of Diabetes Investigation* 10(1): 154-162.
- Gill, P.K., Choo, W.Y. & Bulgiba, A.M. 2012. How useful is clinical scoring in reducing the need for gestational diabetes screening? *International Journal of Diabetes in Developing Countries* 32(2): 69-74.
- Goh, S.N., Rosilawati, W.R.W. & Hamid, N.A. 2018. The influence of maternal gestational diabetes mellitus status and foetal sex on infant outcomes: A registry audit. *International Journal of Public Health and Clinical Sciences* 5(1): 83-96.
- Hasbullah, F.Y., Yusof, B.N.M., Shariff, Z.M., Rejali, Z., Yong, H.Y. & Mitri, J. 2020. Factors associated with dietary glycemic index and glycemic load in pregnant women and risk for gestational diabetes mellitus. *International Journal* of Food Science and Nutrition 71(4): 516-524.
- Hosseini, E. & Janghorbani, M. 2018. Systematic review and meta-analysis of diagnosing gestational diabetes mellitus with one-step or two-step approaches and associations with adverse pregnancy outcomes. *International Journal of Gynaecology and Obstetrics* 143(2): 137-144.
- HTAU. 2017. *Management of Diabetes in Pregnancy*. Health Technology Assessment Unit (HTAU).
- HTAU. 2015. *Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus.* 5th ed. Health Technology Assessment Unit (HTAU).
- Idris, N., Hatikah, C.H.C., Murizahm, M.Z. & Rushdan, M.N. 2009. Universal versus selective screening for detection of gestational diabetes mellitus in a Malaysian population. *Malaysian Family Physician* 4(2-3): 83-87.
- Ismail, N.A., Kasim, M.M., Aizuddin, A.N. & Umar, N.A. 2013. Homeostatic indices of insulin resistance among gestational diabetics in anticipating pregnancy complications. *Gynecological Endocrinology* 29(7): 691-694.
- Ismail, N.A., Aris, N.M., Mahdy, Z.A., Ahmad, S., Naim, N.M., Siraj, H.H. & Zakaria, S.Z.S. 2011. Gestational diabetes mellitus in primigravidae: A mild disease. *Acta Medica* (*Hradec Králové*) 54(1): 21-24.
- Jafari-Shobeiri, M., Ghojazadeh, M., Azami-Aghdash, S., Naghavi-Behzad, M., Piri, R., Pourali-Akbar, Y., Nasrollah-Zadeh, R., Bayat-Khajeh, P. & Mohammadi, M. 2015. Prevalence and risk factors of gestational diabetes in Iran: A systematic review and meta-analysis. *Iranian Journal of Public Health* 44(8): 1036-1044.
- Kalok, A., Peraba, P., Shah, S.A., Mahdy, Z.A., Jamil, M.A., Kampan, N., Sulaiman, S. & Ismail, N.A.M. 2018. Screening

for gestational diabetes in low-risk women: Effect of maternal age. *Hormone Molecular Biology and Clinical Investigation* 34(1): 1-6.

- Kampan, N., Azman, H., Hafiz, I., Mohammad, H., Yee, C.S., Ghani, N.A.A. & Abdullah, Z.M. 2013. Outcome of pregnancy among Malaysian women with diabetes mellitus a single centre experience. *Malaysian Journal of Public Health Medicine* 13(2): 1-10.
- Karaçam, Z. & Çelİk, D. 2021. The prevalence and risk factors of gestational diabetes mellitus in Turkey: A systematic review and meta-analysis. *The Journal of Maternal-Fetal & Neonatal Medicine* 34(8): 1331-1341.
- Kramer, C.K., Campbell, S. & Retnakaran, R. 2019. Gestational diabetes and the risk of cardiovascular disease in women: A systematic review and meta-analysis. *Diabetologia* 62(6): 905-914.
- Landon, M.B., Spong, C.Y., Thom, E., Carpenter, M.W., Ramin, S.M., Casey, B., Wapner, R.J., Varner, M.W., Riuse, D.J., Thorp Jr., J.M. & Sciscione, A. 2009. A multicenter, randomized trial of treatment for mild gestational diabetes. *New England Journal of Medicine* 361(14): 1339-1348.
- Lapolla, A., Dalfrà, M.G., Ragazzi, E., Cata, A.P.D. & Fedele, D. 2011. New International Association of the Diabetes and Pregnancy Study Groups (IADPSG) recommendations for diagnosing gestational diabetes compared with former criteria: A retrospective study on pregnancy outcome. *Diabetic Medicine* 28(9): 1074-1077.
- Lee, K.W., Ching, S.M., Ramachandran, V., Yee, A., Hoo, F.K., Chia, Y.C., Sulaima, W.A.W., Suppiah, S., Mohamed, M.H. & Veettil, S.K. 2018. Prevalence and risk factors of gestational diabetes mellitus in Asia: A systematic review and meta-analysis. *BMC Pregnancy and Childbirth* 18(1): 1-20.
- Li, K.T., Naik, S., Alexander, M. & Mathad, J.S. 2018. Screening and diagnosis of gestational diabetes in India: A systematic review and meta-analysis. *Acta Diabetologica* 55(6): 613-625.
- Logakodie, S., Azahadi, O., Fuziah, P., Norizzati, B., Tan, S.F., Zienna, Z., Norliza, M., Noraini, J., Hazlin, M., Noraliza, M.Z., Sazidah, M.K. & Mimi, O. 2018. Gestational diabetes mellitus: The prevalence, associated factors and foeto-maternal outcome of women attending antenatal care. *Malaysian Family Physician* 12(2): 9-17.
- MedCalc Statistical Software version 19.1.2. 2019. Ostend, Belgium: MedCalc Software.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. 2009. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* 6(7): 1-6.
- Muniswaran, G., Soelar, S.A., Karalasingam, S.D., Bujang, M.A., Jeganathan, R. & Suharjono, H. 2017. Effectiveness of selective risk-based screening for gestational diabetes (GDM) in Malaysia: A retrospective cohort study based on

the National Obstetric Registry (NOR) of Malaysia. *The Medical Journal of Malaysia* 72(1): 46-49.

- Munn, Z., Moola, S., Lisy, K., Riitano, D. & Tufanaru, C. 2015. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *International Journal of Evidence-Based Healthcare* 13(3): 147-153.
- Natamba, B.K., Namara, A.A. & Nyirenda, M.J. 2019. Burden, risk factors and maternal and offspring outcomes of gestational diabetes mellitus (GDM) in sub-Saharan Africa (SSA): A systematic review and meta-analysis. BMC Pregnancy and Childbirth 19(1): 1-11.
- Nguyen, C.L., Pham, N.M., Binns, C.W., Duong, D.V. & Lee, A.H. 2018. Prevalence of gestational diabetes mellitus in eastern and south-eastern Asia: A systematic review and meta-analysis. *Journal of Diabetes Research* 18: 494.
- Nordin, N.M., Wei, J.W., Naing, N.N. & Symonds, E.M. 2006. Comparison of maternal-fetal outcomes in gestational diabetes and lesser degrees of glucose intolerance. *Journal* of Obstetrics and Gynaecology Research 32(1): 107-114.
- Nouhjah, S., Shahbazian, H., Amoori, N., Jahanfar, S., Shahbazian, N., Jahanshahi, A. & Cheraghian, B. 2017.
 Postpartum screening practices, progression to abnormal glucose tolerance and its related risk factors in Asian women with a known history of gestational diabetes: A systematic review and meta-analysis. *Diabetes & Metabolic Syndrome: Clinical Research and Reviews* 11(Supplement 2): S703-S712.
- Shamsuddin, K., Mahdy, Z.A., Rafiaah, I.S., Jamil, M.A. & Rahimah, M.D. 2001. Risk factor screening for abnormal glucose tolerance in pregnancy. *International Journal of Gynaecology & Obstetrics* 75(1): 27-32.
- Tan, P.C., Aziz, A.Z., Ismail, I.S. & Omar, S.Z. 2012. Gammaglutamyltransferase, alanine transaminase and aspartate transaminase levels and the diagnosis of gestational diabetes mellitus. *Clinical Biochemistry* 45(15): 1192-1196.
- Tan, P.C., Ling, L.P. & Omar, S.Z. 2007. Screening for gestational diabetes at antenatal booking in a Malaysian university hospital: The role of risk factors and threshold value for the 50-g glucose challenge test. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 47(3): 191-197.

Wendland, E.M., Torloni, M.R., Falavigna, M., Trujillo, J., Dode, M.A., Campos, M.A., Duncan, B.B. & Dode, A.I. 2012. Gestational diabetes and pregnancy outcomes - a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. *BMC Pregnancy and Childbirth* 12(1): 1-13.

Cheong Lieng Teng* Department of Family Medicine International Medical University Seremban Campus, Jalan Rasah 70300 Seremban, Negeri Sembilan Darul Khusus Malaysia

Foo Ken Yong, Ka Mun Lum & Chan Xuan Hii Ministry of Health Malaysia Ibu Pejabat KKM Blok E1, E6, E7 & E10, Parcel E Pusat Pentadbiran Kerajaan Persekutuan, 62590 Putrajaya, Federal Territory Malaysia

Shen Yung Toh The University of New South Wales Sydney NSW 2052 Australia

Sivalingam Nalliah Department of Obstetrics & Gynaecology International Medical University Seremban Campus, Jalan Rasah 70300 Seremban, Negeri Sembilan Darul Khusus Malaysia

*Corresponding author; email: tengcl@gmail.com

Received: 14 June 2020 Accepted: 31 December 2020